Phase 2 - A parallel-group treatment, double-blind, three-arm study to assess
efficacy and safety of finerenone plus empagliflozin compared with either
finerenone or empagliflozin in participants with Chronic Kidney Disease (CKD)
and Type 2 Diabetes.
Inclusion:
Type 2 Diabetes (T2D)
Chronic Kidney Disease
GFR > 30
UACR > 300
Exclusion:
Type 1 Diabetes (T1D)
Chronic Kidney Disease not on dialysis.
Renal allograft in place or a scheduled kidney transplant.
This is not a complete list of inclusion and exclusion criteria for this study.